10-Q: Origin Materials Faces Going Concern Doubt Amid Losses

Origin Materials, Inc. reported significant net losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern, while facing operational delays and initiating a strategic review.

Summary

• Origin Materials, Inc. reported a net loss of $12.7 million for the three months ended June 30, 2025, and $39.2 million for the six months ended June 30, 2025.
• Revenue from products decreased by 17% to $5.8 million for the three months ended June 30, 2025, and by 19% to $11.2 million for the six months ended June 30, 2025, compared to the same periods in 2024, primarily due to the planned reduction in the supply chain activation program.
• The company had $69.4 million in cash, cash equivalents, and marketable securities as of June 30, 2025, down from $93.6 million at December 31, 2024.
• An impairment charge of $16.6 million was recorded for the six months ended June 30, 2025, related to an agreement for conversion of materials produced by Origin 1.
• The first CapFormer system for PET closures commenced production in February 2025, and the second completed Factory Acceptance Testing (FAT) in July 2025.
• The company's Board of Directors initiated a broad strategic review in August 2025 to maximize shareholder value, exploring options including financing, divestiture, licensing, or sale of the company.
• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months due to ongoing net losses and negative cash flows from operations.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, explicitly stating 'substantial doubt about our ability to continue as a going concern.' This is compounded by increasing net losses, declining revenue, significant asset impairment, and operational delays in key manufacturing scale-up due to external factors like tariffs. While a strategic review is underway, its outcome is uncertain, and the company's liquidity position is precarious, necessitating substantial additional financing to avoid scaling back or ceasing operations. The Nasdaq delisting risk further adds to the negative outlook.

Positives

• The first CapFormer system for PET closures commenced production in February 2025, indicating progress in commercialization.
• The second CapFormer system successfully completed its Factory Acceptance Test (FAT) in July 2025, with four additional lines expected through Q4 2025 and two more in H2 2026.
• Origin 1, the first furanics manufacturing plant, achieved mechanical completion and is operating on demand for long lead time production, preserving the ability to generate small volumes for strategic partners.
• The company initiated a broad strategic review in August 2025, engaging Royal Bank of Canada (RBC) as a strategic and financial advisor, to explore options for accelerating value creation and enhancing access to manufacturing capacity, marketing, distribution, and strategic capital.
• Net cash used in operating activities decreased to $15.7 million for the six months ended June 30, 2025, from $31.7 million in the same period of 2024.
• General and administrative expenses decreased by $2.1 million (10%) for the six months ended June 30, 2025, primarily due to reduced equipment, maintenance, and repairs for Origin 1 and lower stock-based compensation.
• Research and development expenses decreased by $3.6 million (36%) for the six months ended June 30, 2025, mainly due to a reduction in payroll and insurance/facilities expenses.

Negatives

• The company has experienced net losses and negative cash flows from operating activities since its inception, with an accumulated deficit of $77.3 million as of June 30, 2025.
• Net loss for the six months ended June 30, 2025, was $39.2 million, an increase of 17% compared to $33.4 million in the same period of 2024.
• Total revenues decreased by 19% to $11.2 million for the six months ended June 30, 2025, compared to $13.9 million in the same period of 2024, primarily due to the planned reduction in the supply chain activation program.
• An impairment charge of $16.6 million was recorded for the six months ended June 30, 2025, related to the discharge of advance payments and future commitments under a take-or-pay agreement for materials conversion.
• Cash, cash equivalents, and marketable securities decreased to $69.4 million as of June 30, 2025, from $93.6 million at December 31, 2024.
• The company expects to continue to incur net losses and negative cash flows from operating activities for the foreseeable future, raising substantial doubt about its ability to continue as a going concern.
• Delays in CapFormer lines' Factory Acceptance Testing (FAT) are expected to be 30 to 90 days beyond prior expectations, leading to a substantial reduction in 2026 manufacturing output and a smaller reduction for 2027.
• Increased tariff costs (e.g., 15% on European goods, 39% on Swiss goods) are impacting equipment for CapFormer lines, increasing capital requirements and making debt financing more expensive.
• The company relies on a limited number of customers, with the top two customers accounting for approximately 100% of total revenue for the three and six months ended June 30, 2025, posing a significant concentration risk.
• The company's common stock has traded below the Nasdaq minimum $1.00 bid price, leading to a deficiency letter and potential delisting if compliance is not regained by October 6, 2025, or an extended period.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, requiring significant additional financing which may not be available on acceptable terms or at all.
• The company is an early-stage company with a history of losses, and future profitability is uncertain, with expected continued net losses for the foreseeable future.
• Failure to obtain substantial additional project financing and/or government incentives could force delays, reductions, or termination of operations and future growth.
• Some products, like PET closures, have never been made before, leading to potential significant delays or obstacles in design, production, launch, and maintenance, hindering successful commercialization.
• The company has no experience producing products in large commercial quantities, posing technological and logistical challenges for scaling up.
• Construction of manufacturing lines for PET closures or additional furanics plants may not be completed timely or cost-effectively, or at all, due to factors like tariffs, travel restrictions, unexpected construction problems, or regulatory issues.
• Reliance on a limited number of manufacturing facilities for near-term customer demand for PET closures and future intermediate chemical sales creates vulnerability to disruptions.
• Dependence on a limited number of customers for a significant portion of near-term revenue (100% from top two customers for recent periods) poses a high concentration risk.
• The industry is highly competitive, and the company may lose market share to producers of substitute products, including incumbent HDPE/polypropylene closures and fossil-based materials.
• Increases or fluctuations in raw material costs (PET, timber, forest residues) may adversely affect the cost structure and profitability.
• Dependence on third-party suppliers and service providers, some of which are sole source, carries risks of failure to deliver or supply according to schedules, prices, quality and volumes that are acceptable.
• Collaborations, strategic alliances, or licensing arrangements expose the company's intellectual property to competitive risks and limitations, and may not produce anticipated benefits.
• Compliance with extensive environmental, health, and safety laws could require material expenditures, operational changes, or site remediation, and new food safety regulations could hinder market entry.
• Failure to protect proprietary information and other intellectual property rights could harm competitive advantages.
• Potential patent infringement and other intellectual property claims could be costly to defend, result in injunctions, or require costly licensing arrangements.
• Reliance on trade secrets to protect technology means failure to maintain trade secret protection could limit competitiveness.
• The management team has relatively limited experience operating a public company, potentially impacting compliance and operations.
• Failure to maintain effective internal control over financial reporting could result in material misstatements or failure to meet reporting obligations.
• The company currently does not meet Nasdaq listing standards (minimum bid price) and faces potential delisting, which would decrease liquidity and increase volatility.
• Future issuances of debt or equity securities may adversely affect the company, including diluting existing stockholders' ownership interests and depressing the market price of common stock.
• The value of products may be dependent on the value of carbon credits, which fluctuates based on market and regulatory forces outside of the company's control.

Future Outlook

The company expects to continue incurring net losses and negative cash flows from operating activities for the foreseeable future. It anticipates needing substantial additional project financing, including from strategic partners and government incentives, to meet financial projections and expand manufacturing capabilities for PET closures and furanics technology. The company is exploring various strategic alternatives, including equity/debt financing, divestiture, licensing, or a sale of the company, to accelerate value creation and address increased capital requirements due to tariffs. Manufacturing output for 2026 is expected to be substantially reduced, with a smaller reduction for 2027, due to CapFormer line delays.

Management Comments

• "We believe it is prudent to explore strategic arrangements that could help the Company to accelerate value creation from our technology for the benefit of our shareholders."
• "We are considering a range of alternatives encompassing a potential business combination, equity and debt financing, divestiture of assets, technology licensing, acquisition, merger, reverse merger, sale of assets and other strategic arrangements including, potentially, sale of the Company."
• "We anticipate bringing additional CapFormer Systems online as part of our scale-up strategy with our second CapFormer System having completed Factory Acceptance Testing in July, 2025, and four additional lines expected to complete Factory Acceptance Testing on a rolling basis through Q4 of 2025, and another two in the second half of 2026."
• "We experienced a number of delays during this process, including slower subcomponent delivery, procurement, and delivery times, often due to tariff administration and logistics. As a result, we now expect Factory Acceptance Testing ('FAT') for each of our CapFormer lines to be completed 30 to 90 days beyond our prior expectations."
• "As a result, we now expect a substantial reduction in our manufacturing output for 2026 and a smaller reduction for 2027, which may adversely affect our revenue, profitability, and ability to meet customer demand."
• "In response, we are diversifying our manufacturing footprint, including the addition of a European mass production partner, to mitigate the impact of U.S. tariffs and maintain our ability to meet customer demand."
• "At current operating levels, these conditions raise substantial doubt about our ability to continue as a going concern within a year of this Quarterly Report. Accordingly, absent substantial additional financing by the end of 2025, we expect to need to begin scaling back or ceasing certain operational functions and processes, reducing headcount, and potentially implementing other mitigations and contingencies, which may include disposition of assets or sale of the Company."

Industry Context

Origin Materials operates in the nascent but growing sustainable materials industry, specifically targeting the PET closures market and furanics technology for biomass conversion. The company aims to compete with established fossil-based materials and traditional closure manufacturers (HDPE, polypropylene) by offering sustainable, performance-enhanced alternatives. The industry is characterized by strong demand for sustainable solutions, but also faces technical challenges in commercialization at scale, intense competition from incumbents, and sensitivity to raw material prices (PET vs. HDPE/polypropylene, biomass vs. petroleum). Regulatory changes, such as European cap tethering mandates and recycled content requirements, are driving demand for solutions like Origin's PET closures. However, global macroeconomic challenges, including inflation, interest rate volatility, and trade tariffs, are impacting supply chains and increasing costs across the industry.

Comparison to Industry Standards

• The company states it is going to market with what it believes is the 'first commercially viable PET closure,' implying a pioneering position compared to other companies that have not successfully commercialized PET closures at meaningful scale due to technical challenges.
• Origin's approach to PET closure production, utilizing novel applications of thermoforming and slit and fold technologies without custom polymers, differentiates it from traditional injection and compression molding methods used by incumbent HDPE and polypropylene closure manufacturers.
• The company's furanics technology aims to compete directly with petroleum-derived products on performance and price, while offering sustainability and lower carbon footprint, positioning it against large established producers of fossil-based materials.
• The company's reliance on a limited number of manufacturing facilities and high customer concentration (100% from top two customers for recent periods) is a deviation from diversified industry standards, increasing operational and revenue risk compared to more mature, diversified competitors.

Management Changes

Legal Proceedings

• A putative securities class action, 'In re Origin Materials, Inc. Sec. Litig.,' is ongoing in the Eastern District of California, alleging violations of federal securities laws related to the August 9, 2023, announcement of delays for the Origin 2 project.
• Two derivative complaints, 'Thomas Kaspar v. John Bissell, et al.' and 'Travis Tanasse v. John Bissell, et al.,' were filed in March 2025 in the Eastern District of California against certain current and former directors, alleging breaches of fiduciary duty and related claims in connection with the same August 9, 2023, announcement. These cases are stipulated to be consolidated and stayed pending a final decision on any summary judgment motion in the securities class action.

Related Party Transactions

• A legacy stockholder provided a $5.0 million prepayment for product from Origin 1 in November 2016, secured by a promissory note. Repayments of $1.9 million are due on September 1, 2025, and $1.8 million on September 1, 2026. This stockholder also exercised an option to enter a new Offtake Agreement to buy a specified annual amount of product from Origin 2 for an initial term of up to 10 years.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises, potential loss of investment due to going concern doubt, increased volatility and potential delisting from Nasdaq, and reduced share price due to negative financial performance and operational delays.
• **Employees:** Workforce reduction implemented in September 2024, with potential for further reductions if additional financing is not secured, leading to job insecurity and potential morale issues. Loss of institutional knowledge and expertise is a risk.
• **Customers:** May experience delays in product delivery due to CapFormer line delays and reduced manufacturing output, potentially impacting their own carbon reduction, sustainability, and marketing goals. High customer concentration means a loss of a major customer would severely impact revenue.
• **Suppliers:** The company's reliance on a limited number of suppliers, including sole-source providers, and the impact of tariffs on equipment costs, could strain supplier relationships and lead to disruptions.
• **Creditors:** The 'substantial doubt about our ability to continue as a going concern' raises concerns about the company's ability to satisfy its liabilities in the normal course of business, potentially impacting repayment of notes payable and other obligations.

Next Steps

• Obtain substantial additional project financing, including from strategic partners and government incentives, to fund future operations and growth strategy.
• Continue bringing additional CapFormer Systems online, with four additional lines expected to complete FAT through Q4 2025 and two more in H2 2026.
• Diversify manufacturing footprint, including adding a European mass production partner, to mitigate the impact of U.S. tariffs.
• Continue the broad strategic review initiated by the Board in August 2025 to maximize shareholder value, exploring options such as business combination, financing, divestiture, licensing, or sale of the company.
• Regain compliance with Nasdaq's minimum $1.00 bid price requirement by October 6, 2025, or seek an additional 180-day period.
• Assess the potential impact of the 'One Big Beautiful Bill Act' on business and financial results, to be reflected in the Annual Report on Form 10-K for the year ending December 31, 2025.
• Collect remaining accounts receivables of $17.9 million from the legacy supply chain activation program.
• Proceed with the sale of $9.1 million of land held for sale in Geismar, Louisiana, as an additional source of cash.

Key Dates

Recommendation

The filing presents a dire financial situation, explicitly stating 'substantial doubt about our ability to continue as a going concern.' This is the most critical red flag for investors. The company is experiencing significant and increasing net losses, declining revenues, and has a precarious cash position that is insufficient to fund operations for the next 12 months without substantial additional financing. Operational delays in key manufacturing scale-up, exacerbated by tariffs, will further reduce future output and revenue. The high customer concentration and ongoing litigation add to the risk profile. While a strategic review is underway, there is no assurance of a positive outcome or timely capital infusion. The risk of Nasdaq delisting due to low share price further undermines investor confidence and liquidity. Absent immediate and significant positive developments in financing and operations, the company faces a high probability of further operational scaling back, asset disposition, or even cessation of operations, leading to substantial capital loss for shareholders.

Keywords

Sustainable Materials, PET Closures, Furanics Technology, Biomass Conversion, Circular Economy, Renewable Materials, Specialty Chemicals, Manufacturing Delays, Going Concern, SEC Filing, Nasdaq Delisting, Tariffs, Supply Chain, Capital Raise